CA1050886A - Preparation of pyrogen free virus sub-unit vaccines - Google Patents
Preparation of pyrogen free virus sub-unit vaccinesInfo
- Publication number
- CA1050886A CA1050886A CA211,654A CA211654A CA1050886A CA 1050886 A CA1050886 A CA 1050886A CA 211654 A CA211654 A CA 211654A CA 1050886 A CA1050886 A CA 1050886A
- Authority
- CA
- Canada
- Prior art keywords
- virus
- sub
- surfactant
- units
- antigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB48685/73A GB1486557A (en) | 1973-10-18 | 1973-10-18 | Process for the preparation of pyrogen-free sub-unit vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1050886A true CA1050886A (en) | 1979-03-20 |
Family
ID=10449549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA211,654A Expired CA1050886A (en) | 1973-10-18 | 1974-10-17 | Preparation of pyrogen free virus sub-unit vaccines |
Country Status (15)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK276380A (da) * | 1979-07-09 | 1981-01-10 | Univ Iowa State Res Found Inc | Fremgangsmaade til fremstilling af en vaccine mod infektioes kvaeg-rhinotracheitis |
| FR2470795A1 (fr) * | 1979-12-07 | 1981-06-12 | Pasteur Institut | Procede de purification de particules d'origine biologique, notamment de l'antigene de surface du virus de l'hepatite b (aghbs) et les produits obtenus |
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| FR2483779A1 (fr) | 1980-06-05 | 1981-12-11 | Synthelabo | Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins |
| DE19938767C2 (de) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | Spaltimpfstoffe |
| PL362964A1 (en) * | 2000-10-02 | 2004-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3519400A (en) * | 1967-01-25 | 1970-07-07 | Atomic Energy Commission | Method of centrifugal separation and recovery of chemical species utilizing a liquid medium |
-
1973
- 1973-10-18 GB GB48685/73A patent/GB1486557A/en not_active Expired
-
1974
- 1974-10-08 ZA ZA00746398A patent/ZA746398B/xx unknown
- 1974-10-17 DE DE2449530A patent/DE2449530C2/de not_active Expired
- 1974-10-17 DK DK543974AA patent/DK138581B/da not_active IP Right Cessation
- 1974-10-17 NO NO743758A patent/NO142024C/no unknown
- 1974-10-17 BE BE149618A patent/BE821175A/xx not_active IP Right Cessation
- 1974-10-17 CA CA211,654A patent/CA1050886A/en not_active Expired
- 1974-10-17 SE SE7413113A patent/SE426439B/xx unknown
- 1974-10-17 IL IL45870A patent/IL45870A/xx unknown
- 1974-10-17 IE IE2141/74A patent/IE40187B1/xx unknown
- 1974-10-17 JP JP49119836A patent/JPS5082228A/ja active Pending
- 1974-10-17 NL NLAANVRAGE7413642,A patent/NL181553C/xx not_active IP Right Cessation
- 1974-10-17 CH CH1394974A patent/CH611518A5/xx not_active IP Right Cessation
- 1974-10-17 AT AT835074A patent/AT334524B/de not_active IP Right Cessation
- 1974-10-18 FR FR7435179A patent/FR2248054B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK138581C (US20100268047A1-20101021-C00003.png) | 1979-03-12 |
| SE426439B (sv) | 1983-01-24 |
| NL7413642A (nl) | 1975-04-22 |
| NO142024B (no) | 1980-03-10 |
| CH611518A5 (en) | 1979-06-15 |
| DK543974A (US20100268047A1-20101021-C00003.png) | 1975-06-16 |
| BE821175A (fr) | 1975-04-17 |
| AT334524B (de) | 1976-01-25 |
| DK138581B (da) | 1978-10-02 |
| NO743758L (US20100268047A1-20101021-C00003.png) | 1975-05-12 |
| IE40187L (en) | 1975-04-18 |
| ZA746398B (en) | 1976-06-30 |
| GB1486557A (en) | 1977-09-21 |
| DE2449530A1 (de) | 1975-04-30 |
| JPS5082228A (US20100268047A1-20101021-C00003.png) | 1975-07-03 |
| NL181553B (nl) | 1987-04-16 |
| ATA835074A (de) | 1976-05-15 |
| NL181553C (nl) | 1987-09-16 |
| IE40187B1 (en) | 1979-03-28 |
| FR2248054A1 (US20100268047A1-20101021-C00003.png) | 1975-05-16 |
| IL45870A0 (en) | 1974-12-31 |
| AU7444974A (en) | 1976-04-29 |
| FR2248054B1 (US20100268047A1-20101021-C00003.png) | 1978-07-28 |
| NO142024C (no) | 1980-06-18 |
| IL45870A (en) | 1978-03-10 |
| DE2449530C2 (de) | 1985-08-08 |
| SE7413113L (US20100268047A1-20101021-C00003.png) | 1975-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4158054A (en) | Preparation of virus sub-unit vaccines | |
| US3962421A (en) | Method for the disruption of lipid-containing viruses | |
| CA2841604C (en) | Process for producing viral antigen and vaccines | |
| CA1050886A (en) | Preparation of pyrogen free virus sub-unit vaccines | |
| CA2990633A1 (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
| US4206014A (en) | Process for removing detergents from virus-antigen suspensions | |
| US4344935A (en) | Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines | |
| US4064232A (en) | Process for isolating the immunogenic components of influenza viruses | |
| AU2004249802B2 (en) | Improvements in virus production | |
| Tevethia et al. | Antigenic characterization of infectious bronchitis virus | |
| US4140762A (en) | Influenza sub-unit vaccine | |
| EP0009277B1 (en) | Combined vaccine active against newcastle disease and egg production drop caused by adeno-like viruses, process for preparing it, adeno-like and newcastle disease virus strains | |
| Schneider et al. | Purification of rabies virus from tissue culture | |
| Rawls et al. | Arenaviruses: purification and physicochemical nature | |
| US3485718A (en) | Virus purification | |
| AU649728B2 (en) | Vaccines against equine herpesviruses and the preparation thereof | |
| EP4054630A2 (en) | Compositions and methods for producing a viral vaccine with reduced particle size | |
| SE447789B (sv) | Forfarande for framstellning av forsommar-meningo-encephalitis-virus-vacciner och genom forfarandet framstellda vacciner | |
| CN111763661B (zh) | 一种病毒纯化的方法、制备的疫苗组合物及其应用 | |
| NZ204437A (en) | Vaccine preparation:inactivation of virus by nonionic detergent and cis-platinous halide complex | |
| Brady et al. | An adsorbed surface-antigen influenza vaccine and its serological activity in volunteers | |
| Arai et al. | Demonstration of non-infections hemagglutinating particles of rabies virus and isolation of the hemagglutinin by disruption of the virion with Nonidet P-40 | |
| Håheim et al. | LOCALIZATION OF HOST ANTIGENS IN THE EGG‐GROWN INFLUENZA VIRUS PARTICLE: II. Demonstration of the Forssmann Hapten in the Lipid Layer and the “Host Antigen” on the Viral Spikes | |
| SI7913117A8 (sl) | Postopek za pripravo vakcin proti virusu zgodnje-poletnega meningoencefalitisa | |
| AU2007221746A1 (en) | Improvements in virus production |